Lung cancer trial testing blood test and PET scan for spread
Part of Cancer, Lungs & breathing clinical trials.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer that is stage I to IIIB and has not yet been treated.
- You are scheduled to have surgery for your lung cancer.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You do not have another active cancer or serious uncontrolled illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.